SCHEMBL17522789

SCHEMBL17522789

Cc1ccccc1OCCCc1c(C)n[nH]c1C

nearest known ligand 0.97

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 7/20 0.97
▸ MAPT P10636 6/20 0.97
▸ HSD17B10 Q99714 8/20 0.91
▸ LMNA P02545 7/20 0.91
▸ HTT P42858 4/20 0.91
▸ TSHR P16473 1/20 0.91
▸ RECQL P46063 1/20 0.91
▸ GAA P10253 1/20 0.76
▸ TTR P02766 1/20 0.74
▸ MEN1 O00255 5/20 0.72
▸ KMT2A Q03164 5/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ ALDH1A1 P00352 2/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ HPGD P15428 1/20 0.68
▸ CYP2C19 P33261 1/20 0.68
▸ NPSR1 Q6W5P4 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22610058 0.94 HSD17B10 (0.97) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL19801754 0.85 SMN1; SMN2 (0.72) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL15158388 0.85 TTR (1.00) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL17522785 0.76 SMN1; SMN2 (0.78) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL15828247 0.74 TTR (0.71) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL9808080 0.74 ALDH1A1 (0.62) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL11679951 0.74 CYP2D6 (0.61) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL22315310 0.73 SMN1; SMN2 (0.63) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL1592876 0.72 TDP1 (0.60) SMN1; SMN2MAPTHSD17B10LMNAHTT
SCHEMBL23694651 0.72 MAPT (0.54) SMN1; SMN2MAPTHSD17B10LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS MAHA THERAPEUTICS, INC. 2018-01-25 — — US disclosed
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE MAHA THERAPEUTICS, INC. 2016-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021446-A1 SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS SERPINA6, SERPINC1, SERPINE1 SMN1; SMN2 262/4885MAPT 2695/4885HSD17B10 3839/4885
US-20160045609-A1 CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE TTR, TTPA, SERPINA6 SMN1; SMN2 1239/4885MAPT 677/4885HSD17B10 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback